SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global interstitial lung disease market is estimated to be valued at US$ 1578.9 million in 2021 and is expected to exhibit a CAGR of 6.5% during the forecast period (2021-2028).
Key Trends and Analysis of the Global Interstitial Lung Disease Market:
Key trends in the market include increasing engagement of government regulatory organizations in transforming healthcare and medical field using new research and development activities, increasing adoption of drugs for interstitial lung disease pain, drug launches, inorganic activities such as collaborations and others.
The increasing number of drug approvals from regulatory bodies is expected to drive the market growth over the forecast period. For instance, in March 2019, AstraZeneca, a pharmaceutical industry company announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4798
Market players are engaged in research and development activities in order to develop treatment for lung cancer, this is expected to drive the growth of global interstitial lung disease market over the forecast period. For instance, in January 2021, AstraZeneca and Daiichi Sankyo Company Limited, a pharmaceutical company, announced that the datopotamab deruxtecan, monoclonal antibody and Enhertu (trastuzumab deruxtecan), a chemotherapy and anti-cancer drug showed encouraging results from both antibody drug conjugates (ADCs) in patients with advanced or metastatic non-small cell lung cancer (NSCLC).
The increasing number inorganic growth strategies such as collaboration, is expected to drive the global interstitial lung disease market growth. For instance, in November 2020, the Icahn School of Medicine at Mount Sinai, Department of Medicine’s Clinical Trials Office in collaboration with Boehringer Ingelheim International GmbH, announced the first patient has enrolled in a new clinical study to investigate the effect of nintedanib in adult patients having acute lung injury following COVID-19 infection.
Key Market Takeaways:
Increasing number of clinical trials by market key players is expected to drive the growth of the global interstitial lung disease market over the forecast period. For instance, in August 2020, Boehringer Ingelheim Pharmaceutical GmbH, announced that the first patient had enrolled in InPedILD, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between six and 17 years old with clinically significant fibrosing interstitial lung disease (ILD).
Among regions, North America is expected to hold a dominant position in the global interstitial lung disease market over the forecast period, owing to the increasing number of drug approvals by regulatory bodies in the region. For instance, in May 2020, Takeda Pharmaceutical Company Limited, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4798
Competitive Landscape:
Key players operating in the global interstitial lung disease market include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceutical, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd., and Cipla.
Market Segmentation:
- Global Interstitial Lung Disease Market, By Disease Type:
- Interstitial Pneumonia
- Idiopathic Pulmonary Fibrosis
- Nonspecific Interstitial Pneumonitis
- Hypersensitivity Pneumonitis
- Cryptogenic Organizing Pneumonia (COP)
- Sarcoidosis
- Acute Interstitial Pneumonitis
- Global Interstitial Lung Disease Market, By Drug Type:
- Corticosteroids
- Anti-fibrotic Medication
- Pirfenidone
- Nintedanib
- Global Interstitial Lung Disease Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Interstitial Lung Disease Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
Targeted Therapy Market, by Type (Small Molecule Medicines and Monoclonal Antibodies), by Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Renal Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
Lung Cancer Diagnostic and Screening Market, by Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others), Imaging Test ( Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy (Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, Others), By Cancer Type (Non-small cell lung cancer and Small Cell Lung Cancer), by End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
